DS (Asp-Ser)
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A Khavinson-family dipeptide (aspartic acid, serine) marketed for neuroprotection and healthy brain aging. The case rests on an epigenetic mechanism and animal data; human evidence is speculative, with no clinical trials. No adverse effects are reported, but human safety data for DS itself is essentially absent, and unregulated sourcing raises purity concerns. Not an approved drug in the US; sold only as a research-grade product.
Read Full recordStudied uses & evidence
Studied uses(4)
Neuroprotection via epigenetic modulation
SpeculativeBased on molecular modeling of DS binding histone H1.3, not tested in cells or animals.
Calcium homeostasis regulation in neurons
SpeculativeInferred from a proposed gene target linked to calcium signaling, not measured directly for DS.
Potential Alzheimer's disease-relevant neuroprotection
SpeculativeAlzheimer's relevance is extrapolated from related peptides in reviews, not from DS-specific studies.
Evidence limits
- Evidence Level
- Preclinical
Evidence for DS dipeptide is limited to molecular modeling (in silico) studies and broader class-level preclinical data from the Khavinson bioregulator research program. No specific human clinical trials for the DS dipeptide have been published in Western peer-reviewed journals. The parent compound Cortexin has undergone clinical trials in Russia for cerebrovascular disorders and brain injuries.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
No specific adverse effects have been reported for DS dipeptide in published literature
LowKhavinson peptide bioregulators as a class are reported to lack toxic, allergic, or adverse effects in experimental and clinical studies
LowVery limited safety data specific to DS — most safety data comes from the broader Khavinson peptide class
ModerateNo long-term human safety studies have been conducted for DS specifically
ModerateAs with all research peptides, purity and sourcing are critical concerns; unregulated products may contain contaminants
HighTheoretical risk of unintended epigenetic modifications given the chromatin-modulating mechanism, though not observed in available studies
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.